Antihypertensive effects of CBD are mediated by altered inflammatory response: A sub-study of the HYPER-H21-4 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antihypertensive effects of CBD are mediated by altered inflammatory response: A sub-study of the HYPER-H21-4 trial
Authors
Keywords
-
Journal
Journal of Functional Foods
Volume 110, Issue -, Pages 105873
Publisher
Elsevier BV
Online
2023-11-02
DOI
10.1016/j.jff.2023.105873
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study
- (2023) Tanja Dragun et al. ADVANCES IN THERAPY
- CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: A substudy from the HYPER-H21-4 trial
- (2023) Marko Kumric et al. BIOMEDICINE & PHARMACOTHERAPY
- Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study
- (2023) Ana Batinic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-inflammatory effects of CBD in human microglial cell line infected with HIV-1
- (2023) Adriana Yndart Arias et al. Scientific Reports
- Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study
- (2023) Ana Batinic et al. Pharmaceuticals
- Effects of CBD supplementation on ambulatory blood pressure and serum urotensin-II concentrations in Caucasian patients with essential hypertension: A sub-analysis of the HYPER-H21-4 trial
- (2023) Marko Kumric et al. BIOMEDICINE & PHARMACOTHERAPY
- A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
- (2022) Jiangling Peng et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study
- (2022) Marko Kumric et al. Journal of Personalized Medicine
- A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans
- (2021) Caroline A. Arout et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Cannabidiol on the In Vitro Lymphocyte Pro-Inflammatory Cytokine Production of Senior Horses
- (2021) Shelley Turner et al. JOURNAL OF EQUINE VETERINARY SCIENCE
- The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial
- (2020) Salahaden R. Sultan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism
- (2020) Patryk Remiszewski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain
- (2020) Stevie C. Britch et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects
- (2019) Nadia Solowij et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment
- (2019) Marika Premoli et al. LIFE SCIENCES
- Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats
- (2019) Rafał Kossakowski et al. Frontiers in Pharmacology
- Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome
- (2019) Zinah Z. Al-Ghezi et al. BRAIN BEHAVIOR AND IMMUNITY
- Cannabidiol Adverse Effects and Toxicity
- (2019) Marilyn A. Huestis et al. Current Neuropharmacology
- Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study
- (2019) Alexander Patrician et al. ADVANCES IN THERAPY
- Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis
- (2018) Stefania Petrosino et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
- (2018) Andreza B. Sonego et al. BRAIN BEHAVIOR AND IMMUNITY
- Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
- (2018) Eric P. Baron HEADACHE
- Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015
- (2017) Mohammad H. Forouzanfar et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
- (2017) Pal Pacher et al. Nature Reviews Cardiology
- In Vivo Cannabidiol Treatment Improves Endothelium-Dependent Vasorelaxation in Mesenteric Arteries of Zucker Diabetic Fatty Rats
- (2017) Amanda J. Wheal et al. Frontiers in Pharmacology
- Cannabinoids and Cytochrome P450 Interactions
- (2016) Ondřej Zendulka et al. CURRENT DRUG METABOLISM
- Effects of pro-inflammatory cytokines on cannabinoid CB1and CB2receptors in immune cells
- (2015) L. Jean-Gilles et al. Acta Physiologica
- Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1activation
- (2015) Christopher P. Stanley et al. CARDIOVASCULAR RESEARCH
- Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma
- (2015) Francieli Vuolo et al. MEDIATORS OF INFLAMMATION
- Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
- (2014) Fabio Arturo Iannotti et al. ACS Chemical Neuroscience
- The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias
- (2014) Ersöz Gonca et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
- (2013) Francesca Borrelli et al. BIOCHEMICAL PHARMACOLOGY
- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
- (2013) Alline C. Campos et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Is the cardiovascular system a therapeutic target for cannabidiol?
- (2012) Christopher P. Stanley et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Why do cannabinoid receptors have more than one endogenous ligand?
- (2012) V. Di Marzo et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- PPARγ is an E3 ligase that induces the degradation of NFκB/p65
- (2012) Yongzhong Hou et al. Nature Communications
- Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
- (2011) George W. Booz FREE RADICAL BIOLOGY AND MEDICINE
- Acceleration of diabetic wound healing by collagen-binding vascular endothelial growth factor in diabetic rat model
- (2010) Xin Yan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Interleukin 8 and cardiovascular disease
- (2009) S. Apostolakis et al. CARDIOVASCULAR RESEARCH
- Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
- (2009) Teresa Iuvone et al. CNS Neuroscience & Therapeutics
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
- (2009) Francesca Borrelli et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
- (2007) R G Pertwee BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- (2007) A Thomas et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now